Sign In
Buy PCRX
$26.41
-0.560 (-2.08%)
At Close: Jul 31, 2026
Pacira BioSciences Reports Preliminary Net Product Sales of $38.9 Million for November 2020
07:30am, Wednesday, 09'th Dec 2020
-- EXPAREL average daily sales at 103% of the prior year for the month of November 2020 -- PARSIPPANY, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading prov
--Approval based on four pivotal studies showing EXPAREL reduced pain scores and opioid use following surgery-- --EXPAREL is the first long-acting non-opioid option for field block and brachial plexus
Pacira BioSciences Reports Preliminary Net Product Sales of $41.7 Million for October 2020
08:00am, Wednesday, 11'th Nov 2020
-- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 -- -- EXPAREL average daily sales at 112% of the prior year for the month of October 2020 --
Pacira BioSciences to Present at the 2020 Jefferies Virtual London Healthcare Conference
07:30am, Tuesday, 10'th Nov 2020
PARSIPPANY, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences , Inc. (NASDAQ: PCRX) today announced that it will present at the 2020 Jefferies Virtual London Healthcare Conference at 2:05 PM
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
03:46pm, Thursday, 29'th Oct 2020
Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q3 2020 Results - Earnings Call Transcript
Pacira (PCRX) Beats Q3 Earnings and Revenue Estimates
09:15am, Thursday, 29'th Oct 2020
Pacira (PCRX) delivered earnings and revenue surprises of 3.03% and 1.90%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Pacira BioSciences Reports Third Quarter 2020 Financial Results and Business Update
08:00am, Thursday, 29'th Oct 2020
-- EXPAREL average daily sales at 110% of the prior year for the third quarter-- -- Conference call today at 8:30 a.m. ET --
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Tracking John Paulson's Paulson & Company Portfolio - Q2 2020 Update
09:49am, Wednesday, 19'th Aug 2020
John Paulson’s 13F portfolio value increased from $2.62B to $3.13B this quarter. Paulson & Company's largest three positions are Bausch Health, Horizon Therapeutics, and SPDR Gold ETF.
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 17)
Catalent Inc (NYSE: CTLT)
CureVac N.V. (NASDAQ: CVAC) (follow-on buying after a 250% advance on its debut Friday...
Pacira Biosciences (NASDAQ:PCRX) Hits New 12-Month High on Analyst Upgrade
01:24am, Tuesday, 11'th Aug 2020
Pacira Biosciences Inc (NASDAQ:PCRX)’s stock price reached a new 52-week high on Monday after HC Wainwright raised their price target on the stock from $68.00 to $70.00. HC Wainwright currently has
Stocks To Watch: Barrick Gold, Hedge Fund Reveals And Election Plays (NASDAQ:ACIA)
12:08pm, Saturday, 08'th Aug 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Ocular Therapeutix™ Reports Second Quarter 2020 Financial Results and Business Update
12:00am, Friday, 07'th Aug 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
Pacira BioSciences Reports Second Quarter 2020 Financial Results and Business Update
12:00pm, Thursday, 06'th Aug 2020
\-- EXPAREL average daily sales return to year-over-year growth in month of June 2020 -- \-- Conference call today at 8:30 a.m. ET --PARSIPPANY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Pacira BioScie
